Get the Stockscreener App
31.72
4.07%
1.24
After Hours:
31.72
Avidity Biosciences Inc Stock (RNA) Latest News
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo Finance
New Duchenne Results Put Avidity On Course For Filing - Citeline News & Insights
H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com UK
Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia
Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
Avidity Biosciences reports progress in DMD treatment trial - Investing.com India
Avidity Biosciences Announces Positive Topline Del-Zota Data In DMD44 Trial -March 17, 2025 at 07:12 am EDT - Marketscreener.com
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skip - PR Newswire
Bank of New York Mellon Corp Buys 59,295 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
BMO Capital Markets Begins Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Citigroup Initiates Coverage of Avidity Biosciences (RNA) with Buy Recommendation - Nasdaq
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - The Malaysian Reserve
Avidity Biosciences Stock Climbs Amid Promising Prospects - TipRanks
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth By Investing.com - Investing.com South Africa
BMO Capital Initiates Coverage of Avidity Biosciences (RNA) with Outperform Recommendation - MSN
Avidity Biosciences chief scientific officer sells $602,614 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $602,614 in stock - Investing.com India
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference – Company AnnouncementFT.com - Financial Times
Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks - Benzinga India
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Avidity Biosciences to Participate in Upcoming Investor Conferen - GuruFocus.com
BMO starts coverage on Avidity with 'outperform', says first-in-disease therapies in sight - TradingView
BMO Capital Initiates Avidity Biosciences at Outperform With $72 Price Target -March 12, 2025 at 07:10 am EDT - Marketscreener.com
Avidity Biosciences’s SWOT analysis: RNA therapy pioneer’s stock poised for growth - Investing.com India
BMO CAPITAL INITIATES AVIDITY BIOSCIENCES WITH OUTPERFORM RATING By Investing.com - Investing.com UK
Avidity Biosciences (NASDAQ:RNA) Price Target Cut to $48.00 by Analysts at Bank of America - Defense World
Scotiabank Initiates Coverage of Avidity Biosciences (RNA) with Sector Outperform Recommendation - MSN
Avidity Biosciences Announces Inducement Grants Under Nasdaq Lis - GuruFocus.com
Contrasting Teva Pharmaceutical Industries (NYSE:TEVA) and Avidity Biosciences (NASDAQ:RNA) - Defense World
Scotiabank Initiates Coverage on Avidity Biosciences (NASDAQ:RNA) - Defense World
Principal Financial Group Inc. Has $275,000 Position in Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
Scotiabank starts Avidity Biosciences with bullish $70 target - Investing.com India
Avidity Biosciences initiated with an Outperform at Scotiabank - TipRanks
Avidity Biosciences Reports Third Quarter 2023 Financial Results and Recent Highlights - GuruFocus.com
Avidity Biosciences chief program officer sells $172,807 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief program officer sells $172,807 in stock - Investing.com India
13,281 Shares in Avidity Biosciences, Inc. (NASDAQ:RNA) Bought by Y Intercept Hong Kong Ltd - Defense World
Avidity Biosciences (NASDAQ:RNA) Shares Gap Down on Analyst Downgrade - Defense World
Avidity Biosciences’ (RNA) “Buy” Rating Reiterated at Chardan Capital - Defense World
Barclays Has Lowered Expectations for Avidity Biosciences (NASDAQ:RNA) Stock Price - Defense World
Avidity Biosciences (NASDAQ:RNA) Receives "Buy" Rating from Chardan Capital - MarketBeat
Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance UK
Barclays Cuts Avidity Biosciences (NASDAQ:RNA) Price Target to $57.00 - MarketBeat
Handelsbanken Fonder AB Invests $788,000 in Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
Avidity Biosciences Honors Rare Disease Day® and Global Efforts - GuruFocus.com
Avidity Biosciences Advances RNA Therapeutics for Rare Diseases - TipRanks
Avidity Biosciences (NASDAQ:RNA) Issues Quarterly Earnings Results, Misses Expectations By $0.04 EPS - MarketBeat
Positive Outlook for Avidity Biosciences Driven by Promising Pipeline Developments and Strong Financial Position - TipRanks
Avidity Biosciences: Promising Drug Pipeline and Potential Approval for DMD44 Drive Buy Rating - TipRanks
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases – Company AnnouncementFT.com - Financial Times
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com UK
Avidity Biosciences Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
RBC Cuts Price Target on Avidity Biosciences to $61 From $67, Keeps Outperform, Speculative Risk - Marketscreener.com
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Rhumbline Advisers Purchases 4,795 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - Defense World
How Is Avidity Biosciences Fighting for Rare Disease Patients Beyond Drug Development? - StockTitan
Avidity Biosciences: Promising Clinical Developments and Strong Financial Position Justify Buy Rating - TipRanks
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates - MSN
Avidity Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Avidity Biosciences, Inc. SEC 10-K Report - TradingView
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):